<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3764">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786825</url>
  </required_header>
  <id_info>
    <org_study_id>9412M09040</org_study_id>
    <nct_id>NCT00786825</nct_id>
  </id_info>
  <brief_title>Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla</brief_title>
  <acronym>Glycogen</acronym>
  <official_title>Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-range goal of this project is to determine the effects of diabetes and the&#xD;
      hypoglycemic consequences of intensive therapy on in vivo brain glucose metabolism in humans.&#xD;
      We will measure brain glycogen turnover and content in normal controls and subjects with&#xD;
      diabetes under conditions of modest hyper-and hypoglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the morning before the study subjects will report to the Clinical Research Center and will&#xD;
      be asked to stay at the Clinical Research Center for up to 72 hours. You will be asked not to&#xD;
      eat anything after midnight. Small plastic catheters will be placed in two veins in subjects&#xD;
      arms for infusion of glucose and for measuring blood glucose levels every 15-30 minutes.&#xD;
      While subjects are in the study they will continuously receive a small dose of glucose&#xD;
      enriched with 13C label either through the catheter or by drinking a small amount of a sugar&#xD;
      water solution every 15-60 minutes. Subjects will be asked to transfer to the Center for&#xD;
      Magnetic Resonance Research every 6-8 hours (except at night) where they will be asked each&#xD;
      time to conduct an MRI scan as follows: Subjects will be placed on the patient bed in the&#xD;
      magnet room for one-to-two hours. A nurse will stay with the subject at all times during this&#xD;
      study. During some of the scans subjects may be asked to perform a visual task such as&#xD;
      watching a changing checkerboard pattern through a mirror placed in front of their eyes.&#xD;
      After each scan subjects will receive a low carbohydrate meal for weight-maintenance.&#xD;
&#xD;
      Subjects may be asked to receive an infusion of glucose and/or insulin one-to-three times&#xD;
      before and/or after the infusion of 13C-enriched glucose starts. During these infusions the&#xD;
      subject's blood sugar will be maintained either higher or lower than normal levels for up to&#xD;
      3 hours. This will be done to assess the effect of hyper- or hypoglycemia on brain glycogen&#xD;
      metabolism.&#xD;
&#xD;
      Subjects may also be asked several days prior to the study to report to the Clinical Research&#xD;
      Center for a &quot;mock&quot; study to see if they are comfortable with the MRI scan and/or to test&#xD;
      their body's response to either protocol (as described above, but carried out at the Clinical&#xD;
      Research Center). If subjects would like to try the MRI procedure in advance, this test will&#xD;
      not exceed 2 hours. If we need to test the subject's response to the infusion, this&#xD;
      &quot;pre-test&quot; will involve only drawing blood and administering glucose and will be performed as&#xD;
      described for either protocol above, but will last not more than 4 hours.&#xD;
&#xD;
      Magnetic resonance measurements will be performed in the magnet and are very similar to&#xD;
      magnetic resonance imaging exams (MRI). Subjects will always have the possibility to signal&#xD;
      when they feel claustrophobic and wish to be removed from the magnet. The magnetic resonance&#xD;
      measurements will be associated with a regular clunking noise that subjects may initially&#xD;
      find unpleasant. For their comfort they will be offered to wear ear plugs. During the&#xD;
      measurements in the magnet subjects will be asked to lie still for most of the time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2004</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Glycogen Turnover Rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>somatostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 1 diabetes and Hypoglycemia unawareness</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatostatin</intervention_name>
    <description>Somatostatin may be used to suppress endogenous insulin secretion</description>
    <arm_group_label>somatostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Healthy control&#xD;
&#xD;
          -  Must be able to provide informed consent&#xD;
&#xD;
          -  Type 1 diabetes with hypoglycemia unawareness with hemoglobin A1c &lt; 7.5%&#xD;
&#xD;
          -  Poorly controlled diabetics with hemoglobin A1c &gt; 7.5%&#xD;
&#xD;
          -  Subjects with hypoglycemia unawareness must report an inability to recognize at least&#xD;
             some blood glucose values &lt;58 mg/dL during the 3 months prior to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Over 300 pounds&#xD;
&#xD;
          -  Claustrophobic&#xD;
&#xD;
          -  History of ischemic heart disease, arrhythmia, of seizure disorder&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  On medications known to alter blood flow or carbohydrate metabolism&#xD;
&#xD;
          -  Have internally located pieces of metal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth R Seaquist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <results_first_submitted>November 7, 2019</results_first_submitted>
  <results_first_submitted_qc>December 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Hypoglycemia unawareness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT00786825/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT00786825/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Somatostatin</title>
          <description>Type 1 diabetes and Hypoglycemia unawareness&#xD;
somatostatin: Somatostatin may be used to suppress endogenous insulin secretion</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>Healthy control subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Somatostatin</title>
          <description>Type 1 diabetes and Hypoglycemia unawareness&#xD;
somatostatin: Somatostatin may be used to suppress endogenous insulin secretion</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>Healthy control subjects</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="4"/>
                    <measurement group_id="B2" value="57" spread="3"/>
                    <measurement group_id="B3" value="57" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brain Glycogen Turnover Rate</title>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Somatostatin</title>
            <description>Type 1 diabetes and Hypoglycemia unawareness&#xD;
somatostatin: Somatostatin may be used to suppress endogenous insulin secretion</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>Healthy control subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Glycogen Turnover Rate</title>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.23"/>
                    <measurement group_id="O2" value="0.28" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Course of study, 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Somatostatin</title>
          <description>Type 1 diabetes and Hypoglycemia unawareness&#xD;
somatostatin: Somatostatin may be used to suppress endogenous insulin secretion</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>Healthy control subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Seaquist, MD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-9176</phone>
      <email>seaqu001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

